Therapy Areas: Diabetes
US FDA approves Oramed Pharmaceuticals' Investigational New Drug application for human trials of ORMD-0901
18 September 2018 - The United States Food and Drug Administration (FDA) has approved Israel-based Oramed Pharmaceuticals Inc's (NASDAQ :ORMP)(TASE: ORMP) Investigational New Drug application (IN...
Oramed wins US FDA clearance for IND application for ORMD-0901 to treat type 2 diabetes
18 September 2018 - Pharmaceutical company Oramed Pharmaceuticals Inc (NASDAQ:ORMP) (TASE:ORMP) reported on Monday the receipt of approval from the US Food and Drug Administration (FDA) for its Invest...
Opko Resumes Common Stock Trading on NASDAQ
17 September 2018 - - The NASDAQ Stock Market has lifted the trading suspension of US-based healthcare company Opko Health, Inc. (NASDAQ: OPK) shares, the company said.

As noted previousl...
Janssen's Tremfya Improves Long-Term Patient-Reported Outcomes in Patients with Moderate to Severe Plaque Psoriasis
13 September 2018 - - The Janssen Pharmaceutical Companies of Johnson and Johnson (NYSEL JNJ) has released new data that show considerable improvements in long-term patient-reported outcomes in patien...
KalVista Pharmaceuticals Closes Common Stock Offering, Raising USD 78.2m
11 September 2018 - - US-based clinical stage pharmaceutical company KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has closed an underwritten public offering of 4.6m shares, which included the exercis...
ImmusanT Expands Platform to Type 1 Diabetes with Investment from JDRF T1D Fund
11 September 2018 - - US-based clinical stage company ImmusanT, Inc has received an investment from the JDRF T1D Fund, a venture philanthropy fund exclusively devoted to finding and funding the b...